Navigation Links
Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Date:1/31/2008

SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference in New York on Wednesday, February 6, 2008 at 1:00 p.m. ET / 10:00 a.m. PT. Mark G. Foletta, Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, will be providing a corporate overview.

The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at http://www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 1,900 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 The ... today with $25,000 to fund a translational research ... in 2011, the gift was presented at the ... Annual Meeting in Colorado Springs, CO. ... in neurointerventional approaches to neurovascular conditions, SNIS formed ...
(Date:7/31/2014)... , July 31, 2014 Rogne Bioscience, ... Francisco Bay Area , has acquired a licence ... Oxford,s commercialisation company. The potent anti-inflammatory activity of the ... at the University of Oxford,s Sir William Dunn ... which has raised over $1.5 million in seed financing, ...
(Date:7/31/2014)... 31, 2014 North Shore Towers, a luxury ... with GI Energy, one of the nation’s leading combined heating ... upgrade of its 43-year-old CHP system. The original CHP system ... effort to extend the life of the plant, GI Energy ... electrical and heat recovery equipment, while maintaining continuous operation of ...
(Date:7/31/2014)... 31, 2014 Research and Markets ... Market 2014-2018" report to their offering. ... the study of the genetic material or genomes of ... basis for the discovery and development of diagnostic and ... health conditions. Genomics is supported by three major product ...
Breaking Biology Technology:SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... ... Just Test Instruments , ... (Vocus) April 25, 2010 -- Responding to the recent rash of reports of quality failures ... consultations on how to develop and maintain strict gage R&R for entire assembly and test ...
... PLANO, Texas , April 27 A non-profit organization is ... the full amount of its corporate donations.  "Unlike Coca-Cola, Pepsi refuses to ... Greg Quinlan , President of Parents and Friends of Ex-Gays & ... , "This ...
... April 27 Two months after launching a strategic review of ... has signed an agreement to sell United Media Licensing for $175 million ... , , ... the family of the late Charles Schulz , who created the beloved ...
Cached Biology Technology:InterTech Service to Counter Widely Reported Problems in Automotive, Medical Device and Other Industries Requiring Rigorous Quality Standards 2Pepsi Urged to Follow Example of Coca-Cola and Stop Hiding Corporate Donations 2Scripps Announces Sale of United Media's Licensing Business for $175 Million 2Scripps Announces Sale of United Media's Licensing Business for $175 Million 3
(Date:8/1/2014)... UC Davis Center for Neuroscience and Department of ... Engineering Faculty Fellowship from the U.S. Department of ... new work on learning and memory in Ranganath,s ... new project aims to connect neural oscillations, which ... cortex and hippocampus, brain regions that are known ...
(Date:8/1/2014)... Scientists examining a taxonomically confused group of marine ... science: the Australian humpback dolphin, Sousa sahulensis ... Clymene Enterprises. , The study describing the ... 17-year long systematic examination of all available historical ... dolphinsa widespread group of coastal cetaceans ranging from ...
(Date:8/1/2014)... research will provide enormous opportunities for both biological ... replicate any other cells in the body, offering ... spinal cords, treating kidney, liver and lung diseases ... profit is staggering. Prof. Jinhui Chen from Indiana ... research still faces myriad biological, ethical, legal, political, ...
Breaking Biology News(10 mins):Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3
... 15, 2013 A team of investigators systematically analyzed the ... in a rigorous and controlled study of postmenopausal women. They ... symptoms reported by the participants. Their results are published in ... . The influence of low calcium and vitamin D ...
... more soft drinks per capita than people in any ... of all ages, including very young children. Although ... suicidal thoughts in adolescents, the relationship had not been ... for publication in The Journal of Pediatric s ...
... 15, 2013) Primary results from a new ... diabetes treated with the monoclonal antibody teplizumab (MacroGenics, ... of islet cell function, compared to controls. Further ... group that demonstrated especially robust responses ("responders"), suggesting ...
Cached Biology News:Calcium plus vitamin D supplementation does not reduce joint symptoms in postmenopausal women 2Soft drinks and behavioral problems in young children 2ITN type 1 diabetes study identifies subset of patients with strong response to therapy 2ITN type 1 diabetes study identifies subset of patients with strong response to therapy 3
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
...
Request Info...
Human RUNX2/CBFA1 MAb (Clone 232902)...
Biology Products: